With assay results from DE2 and more information on DE3 (maybe DE4) it's awfully hard to see a news release that will not both go a long ways to establishing some sort of base valuation as well as propelling share price higher.

The people at Genuity called it right last time they put out a 'buy' and I would think they don't do this lightly or without a lot of thought. They will be hero's getting it right a second time. Depending upon the results announced, soon please, by Noront it's not unlikely they'll increase their 'target price' as well.